Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | ESRRA | P11474 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL535774 | 0.82 | IDO1 (0.44) | CYP1A2PDGFRBPDGFRATRPA1LMNA | |
| SCHEMBL191864 | 0.79 | HPGD (0.46) | ESRRATRPA1LMNAMAPTHTT | |
| SCHEMBL28658231 | 0.78 | ESRRA (0.37) | PDGFRBPDGFRAESRRALMNAMAPT | |
| SCHEMBL15485154 | 0.78 | MAPK14 (0.46) | — | |
| SCHEMBL17014137 | 0.77 | RECQL (0.41) | CYP1A2LMNAMAPTHTTCYP2C19 | |
| SCHEMBL11057427 | 0.77 | S1PR1 (0.34) | PDGFRBPDGFRAS1PR1SCN5ASCN9A | |
| SCHEMBL15490439 | 0.77 | SMN1; SMN2 (0.41) | CYP1A2ESRRALMNAMAPTHTT | |
| SCHEMBL28928319 | 0.76 | KDR (0.40) | PDGFRAESRRALMNA | |
| SCHEMBL190585 | 0.75 | ALDH1A1 (0.53) | PDGFRBPDGFRAARHTT | |
| SCHEMBL12695281 | 0.75 | MCL1 (0.36) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086741-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
| US-20180000830-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P-59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| US-9850233-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-12-26 | — | — | US | disclosed |
| US-9701670-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| US-20160318909-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| US-20160115152-A1 | Novel Compounds | RESPIVERT LTD. (GB) | 2016-04-28 | — | — | US | disclosed |
| US-20160045512-A1 | Inhibitors of Hemopoietic Cell Kinase (P59-HCK) and Their Use in the Treatment of Influenza Infection | RESPIVERT LIMITED (GB) | 2016-02-18 | — | — | US | disclosed |
| US-9260410-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2016-02-16 | — | — | US | disclosed |
| US-9242960-B2 | P38MAP kinase inhibitors | Respivert, Ltd. (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20160016934-A1 | KINASE INHIBITORS | TOPIVERT PHARMA LIMITED (GB) | 2016-01-21 | — | — | US | disclosed |
| US-20140228410-A1 | P38MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2014-08-14 | — | — | US | disclosed |
| US-20140057915-A1 | KINASE INHIBITORS | TOPIVERT PHARMA LIMITED (GB) | 2014-02-27 | — | — | US | disclosed |
| US-8642773-B2 | P38MAP kinase inhibitor | RESPIVERT LTD. (GB) | 2014-02-04 | — | — | US | disclosed |
| US-20130040995-A1 | NOVEL COMPOUNDS | RESPIVERT LTD. (GB) | 2013-02-14 | — | — | US | disclosed |
| US-8299073-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2012-10-30 | — | — | US | disclosed |
| US-8299074-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2012-10-30 | — | — | US | disclosed |
| US-20120244120-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LTD. (GB) | 2012-09-27 | — | — | US | disclosed |
| US-20120136031-A1 | P38MAP KINASE INHIBITOR | RESPIVERT LTD. (GB) | 2012-05-31 | — | — | US | disclosed |
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2011-12-22 | — | — | US | disclosed |
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | CYP1A2 1349/4885PDGFRB 825/4885PDGFRA 1494/4885 |
| US-20180086741-A1 | KINASE INHIBITORS | SYK, BTK, SRC | CYP1A2 1761/4885PDGFRB 519/4885PDGFRA 688/4885 |
| US-20180000830-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P-59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | HCK, CDK9, PHKG1 | CYP1A2 3677/4885PDGFRB 1827/4885PDGFRA 1852/4885 |
| US-20160016934-A1 | KINASE INHIBITORS | SYK, LYN, BTK | CYP1A2 1402/4885PDGFRB 274/4885PDGFRA 307/4885 |
| US-20160318909-A1 | KINASE INHIBITORS | SYK, LYN, BTK | CYP1A2 1372/4885PDGFRB 302/4885PDGFRA 335/4885 |
| US-20160115152-A1 | Novel Compounds | ESRRA, ESRRB, LTB4R | CYP1A2 235/4885PDGFRB 1503/4885PDGFRA 1456/4885 |
| US-20120244120-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | HCK, CDK9, TTK | CYP1A2 3288/4885PDGFRB 2004/4885PDGFRA 1866/4885 |
| US-20140228410-A1 | P38MAP KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K11 | CYP1A2 862/4885PDGFRB 1428/4885PDGFRA 1859/4885 |
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAP3K1, MAPK3 | CYP1A2 1001/4885PDGFRB 1005/4885PDGFRA 1396/4885 |
| US-20130040995-A1 | NOVEL COMPOUNDS | ESRRA, ESRRB, LTB4R | CYP1A2 235/4885PDGFRB 1503/4885PDGFRA 1456/4885 |
| US-20140057915-A1 | KINASE INHIBITORS | SYK, BTK, LYN | CYP1A2 2533/4885PDGFRB 432/4885PDGFRA 503/4885 |
| US-20160045512-A1 | Inhibitors of Hemopoietic Cell Kinase (P59-HCK) and Their Use in the Treatment of Influenza Infection | HCK, CDK9, TTK | CYP1A2 3288/4885PDGFRB 2004/4885PDGFRA 1866/4885 |
| US-20120136031-A1 | P38MAP KINASE INHIBITOR | MAPK1, MAP3K1, MAP3K11 | CYP1A2 847/4885PDGFRB 1490/4885PDGFRA 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.